Teleflex Inc. (TFX: Quote) said that it receives FDA 510(k) clearance for Antithrombogenic claims on its ARROW peripherally inserted central catheter or PICC with Chlorag+ard Technology.
Teleflex said that in addition to broad-spectrum antimicrobial protection, the pressure-injectable ARROW PICC with Chlorag+ard Technology provides antithrombogenic protection for at least 30 days.
The company said that Chlorag+ard technology uses a proprietary formulation and process providing a controlled release and availability of chlorhexidine on catheter surfaces. The initial FDA cleared claim of 99.99% colonization reduction for at least 30 days against bacterial and fungal pathogens has now been enhanced by the certain ground-breaking claims.
The claims are 61% reduction in thrombus accumulation on catheter surfaces after 30 days; When challenged with infection, 92% reduction in thrombus accumulation on catheter surfaces after 30 days; Reduced thrombotic intraluminal occlusion; Reduction in phlebitis and an average of 72% less intimal hyperplasia after 30 days.
Click here to receive FREE breaking news email alerts for Teleflex Inc and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org